molecules of the month


METTL3 RNA modifying enzyme inhibitor

efficacy in AML PDX model (50 mg/kg IP)

from 250k compound HTS

Nature, Apr. 26, 2021

Storm Therapeutics / University of Cambridge

1 min read

The Storm Therapeutics/Cambridge METTL3 RNA methyltransferase inhibitor, STM-2457, is a first-in-class catalytic inhibitor of the METTL3 RNA modifying enzyme. DNA-methyltransferase and other epigenetic targets such as HDACs have been explored for their potential roles in cancer and other diseases, and this compound brings RNA modifying enzymes into the druggable target space. The compound is highly specific for METTL3, with no inhibition of other RNA, DNA, or protein methyltransferases, despite being competitive with the ubiquitous SAM-cofactor. Human cellular target engagement was demonstrated with a thermal-shift experiment, and an X-ray co-crystal structure helps explain the selectivity observed. While the compound demonstrates activity in patient-derived xenografts (PDX) and on leukaemic stem cell populations, no significant effects were observed in normal hematopoietic stem cells (HSCs).…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: